98%
921
2 minutes
20
Objective: Updated report about the randomized comparison of the effect of radiotherapy on painful osteoarthritis (OA) applying a standard dose vs. a very low dose regime after a follow-up of 1 year.
Patients And Methods: Patients presenting with OA of the hand/finger and knee joints were included. After randomization (every joint region was randomized separately) the following protocols were applied: (a) standard arm: total dose 3.0 Gy, single fractions of 0.5 Gy twice a week; (b) experimental arm: total dose 0.3 Gy, single fractions of 0.05 Gy twice a week. The dosage was blinded for the patients. For evaluation the scores after 1‑year visual analog scale (VAS), Knee Injury and Osteoarthritis Outcome Score-Short Form (KOOS-PS), Short Form Score for the Assessment and Quantification of Chronic Rheumatic Affections of the Hands (SF-SACRAH) and 12-item Short-Form Health Survey (SF-12) were used (for further details: see [1]).
Results: The standard dose was applied to 77 hands and 33 knees, the experimental dose was given to 81 hands and 30 knees. After 12 months, the data of 128 hands and 45 knees were available for evaluation. Even after this long time, we observed a favorable response of pain to radiotherapy in both trial arms; however, there were no reasonable statistically significant differences between both arms concerning pain, functional, and quality of life scores. Side effects did not occur. The only prognostic factor was the pain level before radiotherapy.
Conclusions: We found a favorable pain relief and a limited response in the functional and quality of life scores in both treatment arms. The possible effect of low doses such as 0.3 Gy on pain is widely unknown.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10806033 | PMC |
http://dx.doi.org/10.1007/s00066-023-02152-z | DOI Listing |
J Clin Oncol
September 2025
Carole Mercier, MD, and Charlotte Billiet, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Antwerp, Belgium, Integrated Personalised and Precision Oncology Network, University Antwerp, Antwerp, Belgium; Charlotte Billiet, MD, PhD, Department of Radiation Oncology, Iridium Networ
J Clin Oncol
September 2025
Xingpeng Luo, MD, Bin Li, MD, and Yinglong Xi, MD, Orthopedic Treatment Center, Southern Central Hospital of Yunnan Province (The First People's Hospital of Honghe State), Mengzi City, China; and Zhixiang Chen, MD, Department of Nephrology, Southern Central Hospital of Yunnan Province (The First Peo
Cureus
August 2025
College of Health Sciences, Universidad San Francisco de Quito, Quito, ECU.
Lattice radiotherapy (LRT) is a type of spatially fractionated radiation therapy (SFRT) that enables the delivery of ablative doses to specific internal regions of large tumoral lesions, while surrounding tissues and nearby critical structures receive significantly lower exposure. This technique relies on a spatial distribution strategy that allows dose levels of radiation to be applied within the tumor in a single session or, alternatively, over the course of five sessions. Over time, LRT has gained attention as a promising method for managing large tumors, especially in cases where conventional treatments may pose higher risks or be less effective, offering the benefit of reduced side effects.
View Article and Find Full Text PDFOncol Res
September 2025
Department of Oncology, Affiliated Hospital of Guilin Medical University, Guilin, 541001, China.
Background: The use of third-generation different tyrosine kinase inhibitors (TKIs) is considered the most effective option for treating advanced non-small cell lung cancer (aNSCLC) with epidermal growth factor receptor (EGFR) mutations. However, there is limited information on the efficacy and safety of aumolertinib in patients remains these cases.
Methods: The clinical records of patients receiving aumolertinib as first-line therapy across four hospitals in the Guangxi Zhuang Autonomous Region from April 2020 to December 2021 were retrospectively analyzed, using progression-free survival (PFS) as the primary endpoint and overall survival (OS) representing the secondary endpoint.
Lancet Oncol
September 2025
Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA; Department of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Background: Select patients with metastatic clear-cell renal-cell carcinoma can be treated without systemic therapy, yet few studies have explored this population. We investigated the efficacy of metastasis-directed therapy without systemic therapy in oligometastatic clear-cell renal-cell carincoma.
Methods: This investigator-initiated single-arm, phase 2 trial enrolled patients aged 18 years or older with an Eastern Cooperative Oncology Group performance status of 0-2, histologically confirmed clear-cell renal-cell carcinoma, and one to five metastases.